Who is sponsoring NCT04328948?

NCT04328948 is sponsored by National Cancer Center, Japan.

What drugs are being tested in NCT04328948?

Interventions in NCT04328948: Chemoradiotherapy.

What condition does NCT04328948 study?

NCT04328948 studies Esophageal Squamous Cell Carcinoma.

Is NCT04328948 still recruiting?

NCT04328948 is currently recruiting now. Last updated 22 May 2025.

Last reviewed 2025-05-22 · How we verify

NCT04328948: ARMADILLO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized Controlled Trial Evaluating of Prophylactic Irradiation in CRT for cT1bN0M0 ESCC

Recruiting now Phase 3 Last updated 22 May 2025

What this trial tests

Phase 3 trial testing Chemoradiotherapy in Esophageal Squamous Cell Carcinoma in 280 participants. Currently enrolling.

Timeline

1 July 2020

Primary endpoint
31 March 2030

31 March 2030

Quick facts

Lead sponsor	National Cancer Center, Japan
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	280
Start date	1 July 2020
Primary completion	31 March 2030
Estimated completion	31 March 2030
Sites	1 location across Japan

Drugs / interventions tested

Chemoradiotherapy — full drug profile →

Conditions studied

Esophageal Squamous Cell Carcinoma — all drugs for Esophageal Squamous Cell Carcinoma →

Sponsor

National Cancer Center, Japan

Who can join

20 and older, any sex, with Esophageal Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is conducted to investigate whether modified chemoradiotherapy with elective nodal irradiation reduces the locoregional recurrence that cannot be completely resected by salvage endoscopic resection and preserve esophagus without compromising overall survival.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Influence of radiation dose and predicted tumor invasion depth on local recurrence after definitive chemoradiotherapy for stage 0-I esophageal squamous cell carcinoma: a propensity score-weighted, retrospective, observational study.
Ikawa T, Ishihara R, Matsueda K, Konishi K, et al · · 2022 · PMID 35313853 · DOI 10.1186/s12885-022-09418-2

Verify or expand the search:

Other trials of Chemoradiotherapy

Trials testing the same drug.

NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
NCT07472868 — Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or · Phase 3 · not yet recruiting
NCT07448077 — Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC · Phase 2 · not yet recruiting
NCT07346248 — Postoperative Complications After Neoadjuvant Chemoradiotherapy or Short-course Radiotherapy and Total Neoadjuvant Treat · enrolling by invitation
NCT06810609 — Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC · Phase 2 · recruiting

Other recruiting trials for Esophageal Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07385001 — A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as N · Phase 1, PHASE2 · recruiting
NCT07217171 — A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial · Phase 1 · recruiting
NCT07109726 — A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations · Phase 1, PHASE2 · recruiting
NCT07090499 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors · Phase 1 · recruiting

Other National Cancer Center, Japan trials

Trials by the same sponsor.

NCT07347314 — Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-based Combi · Phase 2 · recruiting
NCT06854939 — A Prospective Study Investigating the Relationship Between Minimal Residual Disease Detection, Monitoring Frequency, and · not yet recruiting
NCT06673628 — Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma Patients · Phase 2 · recruiting
NCT05832827 — First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Art · Phase 2 · recruiting
NCT06159478 — Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume) · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04328948 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Center, Japan
Last refreshed: 22 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04328948.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing